OmniAb, Inc. (OABI) Earnings Call Transcript & Summary

August 6, 2025

NASDAQ US Health Care Life Sciences Tools and Services earnings 39 min

Earnings Call Speaker Segments

Kurt Gustafson

executive
#1

Thanks, operator, and good afternoon to all of you. Kurt Gustafson here, OmniAb's Chief Financial Officer, and I appreciate everyone joining us for our conference call on second quarter 2025 financial results. Slides accompany today's prepared remarks, and you can find them in the Investors section of our website, omniab.com. Before we get started, I want to remind listeners that comments made on this call by OmniAb's management will include forward-looking statements within the meaning of the federal securities laws. Risks and uncertainties are involved in these forward-looking statements, and they could cause actual results to differ materially from any anticipated results. The cautionary statements contained in today's press release and our SEC filings qualify these forward-looking statements. Importantly, time-sensitive information is contained in this conference call, and it is accurate only as of the date of this live broadcast today, August 6, 2025. Except as required by law, no obligation is undertaken by OmniAb to revise or update any forward-looking statements to reflect events or circumstances after the date of this call. Matt Foehr, OmniAb's President and CEO, is joining me on the call today. During today's call, we'll provide highlights on the company's business and operations, partner and technology updates as well as our recent financial results and outlook; and at the conclusion of the prepared remarks, we'll open the call to questions; and with that, let me turn the call over to Matt.

Matt Foehr

executive
#2

Thank you, Kurt. Hello, everybody, and I appreciate you being with us for this Q2 earnings call. I'll begin on Slide #4. During our previous call, I noted that the year kicked off with a healthy volume of deal activity, and that momentum carried into Q2, with multiple new partners brought on board during the first six months, putting us on a trajectory toward one of the best years we've had; we keep observing a strong level and caliber of transactions. We view this as evidence of our distinctive technology platform, which is always advancing and growing, as well as our team's unwavering commitment to innovation that draws on our special perspective within the industry. Our partners are pushing programs forward into human trials, with one new clinical stage program commencing in Q2 and a number of additional ones moving along through development. Turning to the third point on Slide 4, the recent introduction of our xPloration Partner Access Program has gotten an excellent reception, with enthusiastic uptake from current partners and beyond. Just weeks after we launched, we completed a sale and installation of an xPloration system, and we're handling a healthy pipeline of prospects and commercial activity for this new technology, which should contribute accretively to the business and further broaden where our revenue comes from. New partners are being drawn to our platform, and additional programs are being added as a result; we keep generating efficiencies across our operations by capitalizing on our technologies, such as xPloration, and by simplifying how we run our business, all aimed at building lasting and sustainable value for our stakeholders. We've been adjusting our staffing requirements and recently trimmed certain costs within our workforce; this comes on top of the staffing realignment we told you about in February tied specifically to the small-molecule ion channel portion of our business. We entered 2025 with 114 employees, and our headcount going forward stands at 87 employees. Kurt will share some financial specifics when he speaks. To wrap up here, our 2025 outlook is very much where we want it to be, and we believe we're exceptionally well positioned to achieve our strategic objectives of extending the reach of our technologies and carrying out both the current xPloration launch and the forthcoming new technology launches that we're also quite enthusiastic about. On top of that, we're always looking for additional workflow efficiencies and technology breakthroughs in what we regard as a highly scalable business. Now I'll go over a few of our business metrics, beginning on Slide #5; we finished Q2 with 100 active partners. In Q2, we signed an asset deal with Angelini Pharma covering a small-molecule ion channel modulator aimed at Kv7.2, which we covered on our prior call; furthermore, we completed several license agreements, among them new deals with Veraxa Biotech, Duke-NUS, University of Strathclyde, University of Maryland, AB-Ray Bio and an unnamed global CRO. On this slide, you can also see that we've given you some refreshed specifics regarding how our active partners break down by category—discovery, commercial, and academic—plus how those partners are spread out geographically. Our partner base is largely situated in the U.S., but it has been diversifying steadily as we've managed to extend the reach of our platform successfully. Now let's move to Slide 6. As of the quarter's end, you'll note that active programs grew to 381. Momentum has stayed favorable, with a net gain of 18 programs so far this year. Additionally, the upward trend in program additions that began late last year is still going strong. Naturally, attrition is a normal and anticipated part of drug discovery and development in general. We keep observing it and anticipate continuing to observe it, and it can stem from various causes—among them partner decisions about therapeutic area focus and budgets, along with when we receive reports or updates from partners; even so, the net increase of 18 programs year-to-date demonstrates considerable strength and is more than twice the net additions recorded during the first half of 2024. On Slide #7, our 381 active programs are categorized by license type, and the overall contracted downstream economics are summarized. Notably, roughly 99% of active programs carry potential future economics that OmniAb is contractually owed. The remaining 1% generally ties back to legacy agreements involving prepaid licenses signed years ago by businesses we acquired. Antibody Standard Licenses, as we typically call them, account for 90% of the programs, while 7% come through what we term Revenue Share License Agreements, under which we receive a set share of any value form our discovery partners obtain—whether equity, cash, or something else of value. These revenue share arrangements are largely with academic institutions that nurture OmniAb-derived assets ahead of planned corporate formation events. Total remaining contracted potential milestone payments for our antibody programs exceed $3 billion, with an average royalty rate of 3.36%; that 3.36% average represents a rise from the 3.2% average royalty rate we disclosed in November of 2023. Being able to command robust royalties, I believe, mirrors the worth of our technologies and how relevant they are to the industry; it also demonstrates the value our team generates for partners and stakeholders alike. Now, here on Slide 8, we're shining a bit of light on how post-discovery stage programs in our portfolio keep growing, along with how these programs advance into and through development. Several new programs moved forward to the preclinical stage during the quarter, and one more—Immunovant IMVT-1402 for myasthenia gravis—is currently recruiting for a Phase III clinical trial; the rising count of post-discovery stage programs, which grew 22% versus the prior year period, is something we find truly encouraging. The preclinical portfolio is also varied across indications, covering inflammation, fibrosis, renal, dermatology, CNS diseases and more, alongside the traditionally strong oncology presence. What matters here is that these 61 programs, all past the discovery stage, carry roughly $1.3 billion in contracted remaining potential milestones for OmniAb. Potential milestones tied to the later-stage programs have kept climbing, and that climb has been quite striking over the past 8 to 12 months. Here you can also see the $700 million contribution coming from small-molecule ion channel programs that have now advanced into preclinical. In our view, this growth reflects potential value-creating events in the pipeline, the overall progress being made, and our partners' confidence in assets discovered using our technologies. Turning to Slide 9. Active clinical programs plus approved products totaled 32 at the close of Q2. One new OmniChicken-derived program, from Seismic Therapeutics, entered the clinic during the quarter. That makes the third OmniChicken-derived antibody to reach human clinical trials, after programs with Boehringer Ingelheim and Teva. Through Q2, 2 novel programs have begun first-in-human clinical trials in 2025. We have also seen attrition, or a change in development stage, among Phase I assets, with a CN1 program going back from Curon to WuXi, which WuXi now describes as preclinical.

Matt Foehr

executive
#3

There's also a Genmab initiative that started a first Phase I study during Q1, and by Q2 it had left that study. Attrition, as I've mentioned and as we frequently point out, is simply a normal aspect of developing drugs. From conversations with our partners, our expectation remains that roughly 5 to 7 novel OmniAb-derived programs will enter clinical development altogether this year. On Slide #10, you can see the pipeline of our clinical and commercial stage partners for active programs that still carry downstream economics for us. This pipeline, as the visual shows, runs from Phase I on through later stages and product approvals, reading left to right. A program's placement in this graphic reflects whichever status is most advanced across any geography or indication. Over the past couple of quarters, it's been encouraging to watch more and more programs shift rightward in this graphic, and the most recent one now appearing there is Immunovant IMVT-1402, which I mentioned earlier and which is shown in Phase III. Now let's look at Slide 11. There we've called out a few recent partner updates, among them presentations at ASCO by J&J and Merck KGaA. For us, the J&J data that was disclosed for their trispecific 5322 program stands out in particular, given the 100% response rate seen among heavily pretreated multiple myeloma patients. Those initial data were characterized as pointing toward a possible paradigm shift in how these patients are treated. So this program presents a genuine opportunity to substantially raise the standard of care in multiple myeloma. J&J stated publicly that they're eager to see results from the planned Phase II and Phase III trials of the 5322 program. And during their latest earnings call, they drew attention to this data once more, noting that they're now nearer than they've ever been to their goal of curing multiple myeloma. Among the other highlights on this slide: Teva obtained Fast Track designation for TEV-408 in celiac disease; and I should point out that this same program is also undergoing clinical development for vitiligo. In addition, Teva revealed a partnership with Fosun covering TEV-278 — an alliance formed with the aim of speeding up clinical development of this compound, which is currently in clinical trials for treating various cancer forms, melanoma among them. To wrap up my portion here on Slide #12, we've called attention to our recently introduced xPloration Partner Access program. xPloration is a high-throughput single B-cell screening instrument built around machine learning and AI. It delivers 10x the single cell screening throughput of other instruments, letting users screen far more efficiently. In our view, this system offers screening throughput that has no equal, superior hit recovery, and outstanding ease of use together with reliability. We featured xPloration in a presentation at the Boston PEGS Conference in May, where the system earned Best of Show honors. Not long after its introduction, we completed a sale and installation of xPloration with a worldwide partner, which established an additional income channel coming from instrument sales, plus repeat business generated by our patented disposable consumables and software subscription offerings that include maintenance. The launch remains at an early stage, yet feedback from the marketplace could not have been better. We are also assembling a set of potential sales opportunities from our expanding group of collaborators, thanks to the platform's new availability, and we are receiving questions from additional parties eager to join as OmniAb discovery partners, purely so they can gain access to xPloration; through xPloration, we can better equip partners with cutting-edge technologies that raise their odds of success in a highly effective and scalable way; this helps explain why we view xPloration as an excellent addition to our existing primary business, since it advances our goal of facilitating swift creation of breakthrough therapies. What we hear back tells us the timing for xPloration is ideal, given that the sector is recognizing how lab automation and instrumentation deliver value for Big Data generation, which in turn allows AI- and ML-supported screening and selection; we hold great enthusiasm for what this new product could achieve, as it keeps showing our dedication to innovation and customer support while broadening our sources of revenue. So, with that said, I will hand the call back to Kurt now so he can walk through our Q2 financial results. Kurt?

Kurt Gustafson

executive
#4

Thank you, Matt. Moving to Slide 14, I'd like to begin by walking through our revenue. For Q2 of 2025, our reported revenue came in at $3.9 million, versus $7.6 million during the comparable period in 2024. That drop stemmed mainly from fewer milestones being hit during the quarter along with reduced service revenue. The service revenue falloff was driven largely by a small-molecule ion channel program that we discontinued last year — that discontinuation also caused an acceleration of noncash revenue in that quarter, which made last year's figure look inflated. Partially countering the decline was new xPloration revenue this quarter, and that revenue mainly consists of an instrument sale plus sales of various consumables tied to the xPloration platform. On Slide 15, you can see our cost and operating expenses for Q2 2025, which came down to $20.1 million from $23.9 million in the prior-year period. Both R&D and G&A expenses fell relative to last year, and I'll cover some of those specifics next. So if we turn to Slide 16, looking at operating expense: there's a new line item covering costs tied to the xPloration revenue, roughly $300,000 this quarter. That reflects costs for manufacturing the xPloration instrument along with the related consumables sold during the quarter. Research and development expense was $10.9 million, against $13.9 million a year ago, with the drop mostly attributable to reduced stock-based compensation, fewer personnel, and lower external expenses for small-molecule ion channel programs. G&A expense decreased to $7.7 million from $8 million in the same period of 2024, driven mostly by reduced legal fees and lower stock-based compensation expense. The other operating income line contains a $3 million gain from selling the Kv7 asset to Angelini, partly offset by an increase to our CBR liability tied to that sale. Our net loss for Q2 2025 was $15.9 million, or $0.15 per share, compared with a net loss of $13.6 million, or $0.13 a share, in the same period of 2024. As Matt noted, we reduced headcount further in July; that reduction is expected to bring onetime expenses of roughly $1 million, occurring mainly in Q3; we expect the combined effect of the actions taken last February and this July one to deliver approximately $7 million in annual cash savings going forward. If we turn to Slide 17, you'll see the balance sheet dated June 30, 2025. We closed the quarter with $41.6 million in cash, and cash used during the quarter was $2 million. In the quarter, we collected milestone payments for Genmab's 1078 and Acasunlimab, plus the upfront payment from Angelini tied to the Kv7 asset sale. To wrap up, turning to Slide 18, I'll go over what we're projecting for 2025. Our expectation remains that revenue for 2025 lands somewhere in the range of $20 million to $25 million, while operating expense comes in somewhere between $85 million and $90 million. Just to remind everyone, roughly 40% of that operating expense figure is noncash, largely driven by stock-based compensation along with amortization of intangibles, chiefly tied to acquisitions of companies or technology in the past. We're also still anticipating that cash used during 2025 will come in below the amount of cash used in 2024. And lastly, on the tax rate, our guidance hasn't changed — it stays at approximately 0% because of a valuation allowance. With all that said, I'd now like to turn the call over to questions. Operator?

Michael Almisry

analyst
#5

Micheal is sitting in for Puneet at the moment. Nice work on the quarter. First off, I'd like to ask about trends in large pharma compared with small biotech. A lot of CROs have been discussing how small biotech companies are pushing their trials ahead. I'm curious whether any of that is showing up on your side, whether favorably or unfavorably, when it comes to discovery. Anything you can share there, or is that area entirely distinct from, I suppose, the later-stage side?

Matt Foehr

executive
#6

Sure, Micheal, I appreciate the question. Matt here. We've felt good about steady expansion across both partners and programs. Coming out of last year, we began to see genuinely encouraging momentum take hold. That has clearly carried on, and it shows up in the results and figures for Q2. We've enjoyed solid net gains among partners on both sides, which is a useful gauge of our technologies and how applicable they are to the industry, and of how they draw in new partners along with programs. We're also noticing a healthy blend of large pharma partners kicking off new programs alongside smaller ones; so contributions are coming from both, plus academics who are now incubating assets in order to spin them out as companies. But as for what you asked about small versus large, we're seeing it across both — from both.

Michael Almisry

analyst
#7

All right, that's helpful. And a fast follow-up regarding the outlook. I'd like to know whether the guidance you've kept unchanged still leaves out any contribution from xPloration, or whether that unchanged figure now bakes in some expectations, given that you're 1 quarter into the launch.

Kurt Gustafson

executive
#8

Yeah. Like we mentioned, we'd said xPloration would come on top of what we already had. The figure we're showing for Q2 here is a solid beginning for this, though the numbers are fairly modest, yet there's no adjustment to the guidance, and this xPloration ought to add on top of it.

Matt Foehr

executive
#9

Correct. And Micheal, there's also still no change to the — in our view, xPloration adds to and builds up the business, you know, given the way it's meant to operate; this launch has been in the works on our end for a good while now, and it's something we're thrilled about. The response we've gotten has been excellent.

Matt Hewitt

analyst
#10

This is Jackson <<inaudible>> filling in for Matt. Nice work on the quarter. Yeah, I was hoping to dig into xPloration a bit, now that we're seeing revenue come through. I'm wondering if you could give us some color on the pipeline and how that's shaping up — maybe even without specific figures, just some guidance would help.

Matt Foehr

executive
#11

Yes. Yes. Thanks, Jackson. So we rolled out the Partner Access Program in May, mid-May, at the PEGS conference in Boston; honestly, that was an ideal venue to introduce the technology, considering who attends that meeting. The reception we received made us very happy. We got voted Best of Show, which was neat. But a lot — even more importantly, a lot of truly excellent conversation got started there. At this point we have 100 active partners, clearly, who are candidates, so to speak, for xPloration, and for some of them it's more applicable than for others, clearly, simply because of business model differences. But we're genuinely pleased that we managed to sell and deploy an instrument within just weeks of launch at a global partner. And I believe that says a great deal about our positioning. The book of business is filling up very nicely. We're handling a great deal of business activity surrounding it. These are, clearly, capital acquisitions. So the process differs somewhat from a typical technology licensing process; even so, we're truly pleased with the feedback coming our way and the momentum the xPloration team is accumulating and with what the technology is delivering for the business. I should mention as well that we're also seeing interest from parties who aren't OmniAb partners right now, who are kind of leading with xPloration, hoping to become discovery partners, with xPloration specifically in mind. And I think that genuinely reflects some of what I said earlier about this truly being the right moment for xPloration from many different angles.

Jacqueline Kisa

analyst
#12

Nice work on the quarter; Jackie here, filling in for Brendan. I was wondering, for partners already with us who'd like to join the Access Program, how does that timeline shape up? Must they buy an instrument across the board? Or do you also provide a data generation piece on its own for such partners?

Matt Foehr

executive
#13

Yes. Yes, that's a great question, Jackie. Clearly, xPloration — let me take a step back and note first that xPloration has sat inside our internal workflows for a lot of years, correct? And that's roughly what I mean when I say we've spent a while getting ready for xPloration's launch and deployment for partners. xPloration has likewise played a central role in how we tap big data generation, our AI and ML tools branded OmniDeep. All of those remain things we keep doing for our standard discovery partners, correct? So — and that draws partners in not merely through the chance to reach 4 species of animals and novel repertoires of fully human antibodies, but also through those downstream workflow capabilities we've assembled over time that let us hand them a wealth of winners, so to speak, from an antibody sequence perspective. So our partners still receive that. They still receive xPloration by way of us; that being said, certain partners possess their own wet labs and are keen and are running enough work and enough campaigns each year that having an xPloration instrument in-house makes sense for them; so really the answer is no change to the way we engage our partners regarding data generation and sharing; but now some partners clearly can purchase an xPloration instrument. Kurt will add.

Kurt Gustafson

executive
#14

Sure, I'll jump in here, Jackie. Suppose an individual approaches us with interest in an xPloration instrument, and that person isn't a partner at present. In that case, we'd have a conversation and explain that this falls under a Partner Access Program. Should they want to become a partner, we would then arrange and execute a license granting them use of our technology stack, and this could essentially happen concurrently. Once they've signed that license and become a partner, we'd be able to start talking about selling them an xPloration unit. That's the way it would function.

Jacqueline Kisa

analyst
#15

That's fantastic, really useful. Thanks for the detail. Perhaps — clearly, you may not be in a position to share much here, but do you have any sense of where that second tech launch will land — whether it will lean more toward this AI/ML data portfolio area, or more toward the antibody legacy business?

Matt Foehr

executive
#16

Yes. Yes. Good question, Jackie. What I can tell you is that another technology launch is on our plan for this year. Our pattern has been to introduce new technologies at big scientific conferences that align closely with our partner base, correct? The technology we plan to introduce draws on, clearly, the strong ties we've built with our 100 partners and counting, and it also takes advantage of the perspective we have across the industry. So once we launch it, we'll share more. All I'll say is it's coming this year; it definitely fits tightly with our strategic mission of helping partners find antibodies faster and more efficiently. And our view is that it will be quite an impactful one, with plenty of novelty.

Stephen Willey

analyst
#17

Regarding the Janssen trispecific, the results certainly appear pretty compelling. Is that covered under the grandfathered prepaid license arrangement? The reason I'm asking is that I understand the earlier bispecific Janssen had approved, teclistamab, was, as I recall, prepaid as well.

Matt Foehr

executive
#18

Steve, that's a fair question. You're right about the economics that were disclosed for the Janssen deal. As you've framed it here, though, it wouldn't actually count as prepaid. There are in fact $35 million in milestone payments tied to first sales. That matches the same approach disclosed when TECVAYLI was approved and launched in the U.S. and Europe. So payments are tied to launch. So it wouldn't — this is not a license that's been fully paid.

Stephen Willey

analyst
#19

Got it, that makes sense. And I realize xPloration is still at an early stage, so providing guidance on much of anything right now is probably tough. Still, I'm just wondering whether you folks might have a ballpark figure you'd be willing to share regarding how the recurring consumable and subscription revenue stream could look on a per instrument basis. Would that be something you'd disclose? Or is there perhaps some kind of industry benchmark you could direct us toward?

Kurt Gustafson

executive
#20

Yeah, that's a fair question, Steve. What I'd say is we do have projections for what we believe those figures could be, though the truth is it shifts based on which customer is using it. So at this stage I don't believe we're prepared to say what those projections amount to, and they could differ based on what type of customer is operating the instrument. So, Matt, I don't know if there's anything to...

Matt Foehr

executive
#21

Yeah, I believe it remains — yeah, there isn't much else to say besides the fact that we're still in the early stages. However, on the back end, this is a business with high margins, and that, in my view, is a very good sign for the xPloration line.

Stephen Willey

analyst
#22

All right. So you mentioned that the Seismic molecule is the third antibody derived from OmniChicken to reach the clinic. Is there a rough sense of what share of those assets are preclinical or further along? I believe those 61 assets also come off that platform. And does this technology usually bring in a somewhat higher royalty rate compared with the average — compared with the overall average across the portfolio you gave us?

Matt Foehr

executive
#23

Yes. Steve, clearly, royalties vary when you look across the entire portfolio, correct? And as that mix has changed, the average royalty has been improving as the portfolio mix evolves. Broadly speaking about the chicken platform, like I mentioned, we now have 3 OmniChicken-derived antibodies that have entered the clinic. Chicken generally encompasses a number of technologies, our standard OmniChicken, which clearly is a chicken that generates fully human antibody sequences. We also have OmniClic, a chicken with a common light chain that likewise generates fully human sequences, really built specifically for bispecifics; we launched OmnidAb fairly recently, roughly 1.5 years ago, which is a chicken that generates domain antibodies, which are really compelling in CNS and other areas. And then we keep innovating around the chicken too. It's a highly differentiated technology for many reasons. Regarding the questions about the 61 programs that are post discovery stage or preclinical or beyond, there certainly are a number of chicken programs among them. In fact, we have an OmnidAb in there as well, which is a fairly quick progression for a newer technology. But we haven't really broken it down by source technology at this point.

Analyst

analyst
#24

Carter here, filling in for Conor. Nice work on the quarter. I wanted to ask about how you plan to run the xPloration business. Is the main idea to sell instruments, plus consumables on top of that? Or are you aiming for something along the lines of a reagent rental arrangement with xPloration?

Matt Foehr

executive
#25

Yes. Instruments get sold. That's correct, the picture you painted, in which partners purchase instruments from us. And after that point, they'll also purchase proprietary consumables from us, along with a software license that includes maintenance. Two main consumables exist, and those are chips and plates, both required when the instrument is run.

Analyst

analyst
#26

Great. I'd like to congratulate you on the new programs and partners. When you examine your funnel of people evaluating the platform, which themes stand out regarding the programs your partners are investigating? Has there been a shift from oncology toward CNS or infectious diseases? Or might you share just general themes about what you're observing at this moment?

Matt Foehr

executive
#27

Yes. Excellent question. One aspect we consider when we innovate around new technologies is not just where the industry stands today, but where it is going. And I believe now, with 381 programs expanding and over 100 partners continuing to grow, we hold a fairly interesting vantage point on the industry. When we consider the technologies that our partners are looking for, we also think about how to make our platform more diverse and, I should say, our portfolio more diverse in terms of therapy area or other applications. So we examine our preclinical assets, and we see oncology, which is no surprise in this industry, but we also see inflammation, fibrosis, renal, dermatology, and a growing subset of CNS diseases. We see some metabolic — we also see a lot of interesting trends in the discovery space, and my perception is that as big pharma begins to take bigger swings at bigger areas, we see that reflected in the kinds of targets they're going after. It gives us an interesting perspective on the sector, and at the same time, we're noticing quite a bit of variety taking shape in what we have coming through.

Matt Foehr

executive
#28

We’re grateful to each of you for being on the call today. Your interest in OmniAb and your engagement with us mean a lot. At our next conference call, scheduled for early November, we’re eager to talk through the financial results for our third quarter. Until then, we expect to take part in quite a few investment conferences over the weeks and months ahead, and we’ll share those specifics before long. So thank you once more, and enjoy the rest of your afternoon.

Operator

operator
#29

That wraps up the conference call for today, everyone. We appreciate all of you joining in. At this point, feel free to hang up. Enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.